

The Psychopharmacologic Specificity of the Lithium Ion: Origins and Trajectory

Jair C. Soares, M.D., and Samuel Gershon, M.D.

This article examines the development of lithium therapy since its dramatic introduction into psychiatry in 1949. Since that time, lithium has been examined in the treatment of a variety of neuropsychiatric conditions, but it is in the treatment of bipolar disorder that it is most effective. This suggests that it has specificity in the treatment of this disorder. These findings are very relevant as they suggest that understanding the mechanism of action of lithium in bipolar disorder may hold keys to elucidating its pathophysiology and to developing newer and more effective treatments. We review the published data on the effectiveness of lithium in bipolar disorder and various neuropsychiatric conditions and also the available data on anticonvulsants and newer therapeutic agents in the treatment of this condition. *(J Clin Psychiatry 2000;61[suppl 9]:16–22)*

The time course of the development of lithium since its introduction in 1949 spans the professional career of one of us (S.G.).^{1–3} My role here is thus of a historian and participant in the evolution of these events. Cade's paper published in 1949 was entitled, "Lithium Salts in the Treatment of Psychotic Excitement."⁴ This report published in the *Medical Journal of Australia* did not engender much excitement or interest outside Australia. This report, however, heralded a number of dramatic events. Lithium has a unique and pivotal position in psychopharmacology. It preceded the introduction of chlorpromazine into psychiatry and in fact fired the first barrage that initiated the modern era of psychopharmacology. With lithium, however, there was a phenomenal lag between its discovery and acceptance in usage in the United States. The time interval is remarkable. It was not approved by the Food and Drug Administration until 1970. Even after this, there was little commercial interest or marketing devoted to it.

Looking closely at the first accounts by Cade⁴ on the evolution of his work that led to his clinical report, we see that serendipity was a major contributor to these momentous events. The story unfolds along a fortuitous path. The short version starts with an interest in pursuing a possible toxin present in urine as a cause of psychosis. The basis of

these ideas lay in Cade's feeling that mania might represent a state of intoxication arising as a result of an excess of some normal metabolites, while depression represented the effects of abnormally low levels of the same metabolites. Urine samples were collected from manic, depressive, and schizophrenic patients as well as from normal controls. The urine was then injected intraperitoneally into guinea pigs. That from manic patients proved to be more toxic than urine from the other groups, although all the samples led to deaths among the animals. Cade reported his observations on the guinea pigs thus: "That after an injection of a solution of lithium they could be turned on their backs and that, instead of their usual frantic fighting behavior, they merely lay there and gazed placidly back at him."⁴

This experience sets a pattern for many subsequent discoveries in psychopharmacology. Even with serendipity, the next major contribution was made by the clinical investigator himself. In the case of Cade, whatever inclarity existed in his preclinical work, once he observed the effects of the treatment on patients, he was uncannily prescient. On the basis of his observations that lithium had a calming effect in guinea pigs, the Australian psychiatrist administered lithium to 6 manic patients and found remarkable benefits in all of them. In 3 of 6 patients with dementia praecox, there was only a quieting effect, and no effects in the others, and in 3 chronic depressive psychotic patients, there was no effect at all. These findings led Cade to comment: "The effect on patients with pure psychotic excitement—that is, true manic attacks—is so specific that it leads to speculations as to the possible etiologic significance of a deficiency of lithium ions in the genesis of the disorder."⁴ The role of lithium deficiency in the pathogenesis of the disorder, of course, has not been supported by subsequent work. Yet, another observation about his clini-

From the Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pa.

Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

Portions of this article have been derived from previous publications by the authors presented at the "1949 Lithium-Lexington 1999 Conference" on May 7, 1999, in Lexington, Ky.

Reprint requests to: Samuel Gershon, M.D., Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara St., Pittsburgh, PA 15213 (e-mail: gershons@msx.upmc.edu).

cal report should be highlighted—the original therapeutic dose fortuitously proved to be the usual optimum dose, that is, 1200 mg of lithium citrate or 600 mg of lithium carbonate thrice daily.

In regard to his clinical findings with lithium, Cade presented some quite dramatic constructs:

1. The concept of lithium specificity, that is, the therapeutic target being “true manic attacks.”
2. His follow-up observation with his small patient sample of the potential of prophylaxis. He raised the possibility for the first time in psychopharmacology that continued treatment may prevent a recurrence of the disease, viz., mania.
3. The concept (the most remarkable within the therapeutic context of the time) that an agent might treat manic excitement without secondary behavioral effects, such as drowsiness, sedation, hypotension, or other neurologic side effects. This profile is still a goal that we would like to attain with our current and yet to be discovered agents, i.e., (a) specificity, (b) predictability, (c) freedom from side effects, (d) potency and efficacy in the majority of cases of the disorder.

Lithium has recently been suggested again to be a specific treatment for bipolar disorder.^{5,6} In this article we briefly review the findings of lithium trials in various neuropsychiatric disorders that gave subsequent confirmation to the notion of lithium’s specificity, and we review emerging concepts with the new agents that have become available for the treatment of bipolar disorder.

The first clinical paper on lithium in the world literature following Cade’s report on the treatment of 6 manic cases was published by Noack and Trautner in the *Medical Journal of Australia* in 1951.⁷ When they reported the results of lithium treatment of 100 patients with various psychiatric disorders, including 30 patients with mania, all but one improved, again supporting the idea of specificity. Noack and Trautner⁷ introduced the use and stressed the importance of measuring plasma lithium levels for safety monitoring and proposed the concept of therapeutic plasma levels. Cade did not utilize such a monitoring procedure, and other studies in Australia reported cases of lithium poisoning without monitoring. It is also of interest that the methodology for electrolyte assays was developed by Dr. Victor Wynn⁸ in the same department (Physiology) as Dr. Trautner at the University of Melbourne.

I will digress to mention another study carried out by Trautner and colleagues entitled “The Excretion and Retention of Ingested Lithium and Its Effect on the Ionic Balance of Man.”⁹ This study raised an interesting concept of the differential pattern of retention and excretion of the lithium ion in manic versus nonmanic subjects. These findings also furthered the suggestion of therapeutic specificity of lithium in “mania,” i.e., “typical” mania.

Following these Australian reports, publication activity was limited to several French reports using lithium in states of agitation as well as manic disorders, and in 1953, a single report in the Italian literature. Over the subsequent 5-year period there were a few more French reports,^{10,11} 2 Italian,^{12,13} 2 Czech,¹⁴ and one English.¹⁵ Thus, there was no storming of the barricades for publication on lithium usage.

Then, a report in 1960 in the United States suggested that lithium had little or no effect on a variety of psychiatric disorders, including schizophrenia, epilepsy, premenstrual tension, and sociopathy but that it was highly efficacious in manic patients.¹⁶ There were 2 early contributions from Canada, Kingstone in 1960¹⁷ and Nassr in 1966.¹⁸ Both reported specific activity in mania. In the United States, reports appeared in the 1960s by Wharton and Fieve¹⁹ and Schlagenhaut and others.²⁰

CLINICAL TRIALS OF LITHIUM

Bipolar Mania

Lithium is in general the most effective medication for acute mania, producing improvement in about 70% to 80% of cases.^{5,6,21–24} Two studies found neuroleptics to be superior.^{25,26} Lithium has been shown to be at least as effective or superior to neuroleptics in various controlled trials.^{27–32} In these studies, lithium was more specific for the core manic symptoms (affective symptoms, ideational symptoms), whereas neuroleptics were generally as good or more effective for hyperactivity and psychomotor agitation, suggesting that the main effects of neuroleptics would involve nonspecific sedation, rather than a true antimanic action.

Response rates have varied in different samples of bipolar patients. In typical “pure” manic states, lithium seems to be the most effective, while in mixed states, atypical, or secondary mania, the response rates tend to be lower, with reports of response rates as low as 29% to 42%.^{33–37} In conclusion, lithium is most effective in “typical” cases of bipolar disorder, suggesting specificity for its action in this condition.

Bipolar Prophylaxis

Cade’s original report mentioned a preventive effect on recurrent mania in some of his patients. Since then, many studies, both open and controlled, have documented the effectiveness of lithium treatment for prophylaxis of the manic and depressive phases of bipolar disorder.^{38–47} Generally, the typical bipolar patients are the ones who appear to respond better. Data from naturalistic studies show lower response rates, with failure rates of up to 70% in some studies.^{48,49} This change in response rates has occurred over time. Early studies reported failure rates of 20% to 30%.¹⁶ Then, reports in the 1960s and 1970s reported failure rates on average of 33%,⁵⁰ and some studies

presented failure rates of over 55%.⁵¹ In particular, patients with mixed states or atypical features appear to have low response rates to lithium treatment.^{6,24,52} The higher response rates found in lithium's early trials have been disputed,⁵³ but the prevailing view is still that lithium is the most effective agent in the treatment of bipolar disorder, with effectiveness demonstrated in several controlled studies.^{5,54} This superior efficacy in bipolar disorder is consistent with the hypothesis of lithium's specificity in the treatment of this disorder.

The Characteristics of Lithium Responders

Classic manic states and mania followed sequentially by euthymia and depression predict good prognosis on lithium prophylaxis.⁵⁵⁻⁵⁷ Mania with mixed or dysphoric features, rapid cycling, and mania secondary to medical conditions respond poorly to lithium.^{30,50,58-60} Patients with high frequency of previous episodes^{61,62} and comorbid substance abuse or personality disorders are also less responsive.⁶²⁻⁶⁶ Family history of mood disorders is related to better response to lithium prophylaxis.^{62,66} In another study,⁶⁷ family history of bipolar disorder, but not unipolar depression, was shown to be related to positive lithium response. These family data, if confirmed, also point to a specificity of lithium for bipolar disorder. Grof et al.⁶⁸ recently readdressed this question and found that a primary diagnosis of affective disorder, episodic course, and family history of bipolar illness were the best predictors of lithium response in the maintenance treatment and remission with *restitutio ad integrum*. In the bipolar II population, lithium is also an effective prophylactic treatment.^{41,69} It is effective in the prophylaxis of hypomanic episodes but may not reduce the frequency of depressive episodes. However, the depressive episodes may be less severe.⁴¹ Thus, lithium is highly effective in the prophylaxis of bipolar disorder, types I and II. It is not as effective in atypical bipolar patients, rapid cyclers, and patients with organic mania, dysphoric mania, and comorbid psychiatric disorders. These studies of predictors of lithium response also give strong support for the idea of lithium's specificity, with typical features predicting response.

Bipolar Depression

Lithium has significant effects in the acute treatment of depression, in particular, depression associated with bipolar disorder.⁷⁰⁻⁷³ However, it is generally not as effective as antidepressants. This superior effectiveness for bipolar in comparison with unipolar depression is also consistent with the hypothesis of its specificity in bipolar disorder.

Unipolar Depression

Lithium was demonstrated to have therapeutic effects in unipolar depression in the acute treatment and in prophylaxis.^{69,74-77} In some countries, it is a popular and even favorite treatment for prophylaxis of recurrent unipolar

depression. The role of lithium as an augmentation agent in refractory depression has been well studied and documented,^{78,79} with findings that it has a clear role for this indication. In conclusion, lithium has acute antidepressant effects in unipolar depression and also some prophylactic action, but it is generally not as effective as antidepressants for acute treatment or prophylaxis of unipolar conditions.⁵¹ Its effects in unipolar depression are apparently smaller than the effects in bipolar depression, once again suggesting specificity for bipolar disorder.

Schizoaffective Disorder

Johnson et al.^{28,80} found a substantially better response rate to lithium treatment in bipolar as compared with schizoaffective patients. These studies found that there were no significant benefits with lithium, with some patients exhibiting worsening of thought disorder. Chlorpromazine on the other hand produced significant improvement. Other reports found lithium to have some beneficial effects for cases of schizoaffective disorder.^{55,81-84} Generally, the more prominent the affective component, the more effective lithium is. In particular, if manic symptoms are prominent, lithium has been shown in these studies to have significant therapeutic effects. However, in most cases, the successful pharmacologic management of schizoaffective disorders requires associated antipsychotic treatment, which often is the mainstay of treatment.

A prophylactic treatment trial⁴⁵ found lithium to be substantially more effective in bipolar than in schizoaffective patients. Thus, there are 2 distinct points of view: one proposes a continuum diagnostic concept and the other, separate and discreet diagnostic entities.

Schizophrenia

Lithium has been administered to schizophrenic patients in various uncontrolled and controlled studies,^{6,16,85-87} with marginal or no therapeutic effects. The overall results of these studies allow us to say that there is no demonstrated effectiveness of lithium for schizophrenic symptoms. In some studies, there were suggestions of therapeutic effects, which were most often due to an affective component associated with the condition.^{83,88,89} In a review of the literature,⁸⁵ it was concluded that lithium might benefit those cases with "psychomotor acceleration and periodicity." Therefore, the results of these studies strongly suggest that lithium has specificity in its actions for bipolar disorder.

Aggressiveness

Lithium has been demonstrated to have therapeutic effects in some cases of aggressiveness,⁹⁰⁻⁹⁵ in particular, cyclic aggressiveness. A placebo-controlled, crossover discontinuation study showed that lithium had significant effects on cyclic aggressiveness, violent explosive behavior, and mood swings in children.⁹¹ This study demon-

strates that the pharmacologic spectrum of lithium may include these key components.

Substance Abuse

Lithium has been examined as a potential treatment for alcohol and cocaine abuse or dependence. The claims for alcoholism date back to a 1974 double-blind controlled study⁹⁶ reporting efficacy. Several subsequent studies supported this. The Dorus et al.⁹⁷ study involved 457 depressed and nondepressed alcoholics. No significant effects of lithium were found in either patient group. Most of the studies in alcoholics demonstrated that lithium has no significant therapeutic effects,⁹⁷⁻⁹⁹ even though there may be effects in associated affective symptoms.¹⁰⁰ In cocaine addicts, it was suggested to potentially have therapeutic effects in some,¹⁰¹ but not all¹⁰² open trials; no controlled evidence supports any therapeutic effects of lithium in these conditions.

Other Conditions

Lithium has also been examined in obsessive-compulsive disorder¹⁰³ and premenstrual syndrome^{104,105} and generally does not seem to be helpful in these conditions. In compulsive gambling, eating disorders, and hypersomnia states, it has been suggested to have positive effects in anecdotal reports,¹⁰⁶⁻¹⁰⁹ but no controlled evidence to date supports any therapeutic effects of lithium in these conditions.

OTHER THERAPEUTIC AGENTS

Carbamazepine

Carbamazepine was initially used in bipolar disorder patients in studies conducted in Japan, which suggested its therapeutic potential.¹¹⁰ To date, several double-blind controlled studies demonstrate its effectiveness in the treatment of mania and also suggest its prophylactic effects.¹¹¹⁻¹¹⁶ However, its effectiveness in prophylactic treatment in comparison with lithium is not clearly determined.¹¹⁷ These studies also suggest that, for patients with mixed states, rapid cycling, treatment refractoriness, or neurologic abnormalities, carbamazepine may be more effective than lithium.¹¹⁸⁻¹²²

Valproate

Valproate, an anticonvulsant introduced in the United States in 1996, has been shown in controlled studies to have effectiveness for treatment of bipolar mania.^{57,123-125} There is also a suggestion of effectiveness superior to lithium for patients with mixed states, rapid cyclers, and refractory patients.^{58,126-128} However, the results of a multicenter study, which examined the effectiveness of valproate in prophylaxis in comparison with lithium, are not yet fully published. Thus, its comparative effectiveness to lithium for this indication has still to be demonstrated.¹²⁷

New Anticonvulsants

Lamotrigine. Lamotrigine is an effective antiepileptic medication that has been suggested to be effective in the treatment of bipolar disorder. Initial open reports and more recent controlled trials suggested its effectiveness in the treatment of mania and also in the treatment of bipolar depression.^{127,129-131} It was also suggested to be effective in rapid cyclers¹³² and in refractory cases.^{131,133} The potential role of lamotrigine in the prophylactic treatment of bipolar disorder remains to be examined.

Gabapentin. Gabapentin is another effective antiepileptic medication whose potential as a mood stabilizer has recently emerged. Retrospective reports and open trials suggest its effectiveness in bipolar disorder.¹³⁴⁻¹³⁷ It was also suggested to be effective in bipolar depression in one open trial.¹³⁸ However, its potential remains to be further examined in double-blind, placebo-controlled studies. Such a study has recently been conducted.¹³⁹ Bipolar patients experiencing mania, hypomania, or mixed state and with ongoing lithium, valproate, or lithium and valproate combination therapy were enrolled. One hundred seventeen patients entered the study. Both the gabapentin and placebo groups had a decrease in total Young Mania Rating Scale from baseline to endpoint, but the decrease was statistically significantly greater in the placebo group than in the gabapentin group ($p < .05$). No difference between treatments on the Hamilton Rating Scale for Depression was observed.

Calcium Channel Blockers

Verapamil. Initial open trials and preliminary controlled trials suggested that verapamil would be effective in the treatment of bipolar disorder.¹⁴⁰⁻¹⁴³ However, a recent double-blind, controlled study failed to demonstrate its effectiveness in this condition.¹⁴⁴

Nimodipine. There are anecdotal reports, open studies, and preliminary controlled trials suggesting that nimodipine would be an effective treatment for bipolar disorder.^{122,145-150} Double-blind, placebo-controlled studies are needed to examine its efficacy further.

Combination Therapy

Current reports suggest that lithium, even when augmented by antidepressants, benzodiazepines, and neuroleptics, is inadequate for more than half the bipolar patients. Denicoff et al.¹⁵¹ reported that response to random-assignment monotherapy for 1 year and crossover in the second year was 33.3% for lithium and 31.4% for carbamazepine, and for combination treatment during the third year was 55.2% with a larger differential effect in rapid cyclers. However, the sample size of 18 was small and subsamples were 6 or 7 patients. Still, 30% to 40% were inadequately responsive. The definition of response in this study is complex. A strong belief has developed that combination therapy may be necessary and beneficial in

some cases. However, the data available on combination therapy are not adequate to reach firm treatment recommendations. More systematic clinical trials are essential before proposals can be developed for rational combination pharmacotherapy.

CONCLUSIONS

The research findings over the past 50 years support Cade's original proposition that lithium is most effective in bipolar disorder.⁴ It is particularly beneficial for the acute treatment of mania and its prophylaxis and also has positive effects in the treatment of depression in bipolar patients. Thus, several authors have proposed that the unique targets with lithium are the specific features of recurrence, cyclicity, episodicity with affective features, and intervals of remission that optimally return to normality. This paradigm of specificity in psychopharmacology may prove to be very useful for elucidating the pathophysiology of the disorder. A better understanding of lithium's mechanism of action in this condition may result in elucidating the basic mechanisms involved in causation of this condition and guide future drug development efforts in this field.

New agents have appeared for the treatment of bipolar disorders. However, based on the evidence reviewed here, lithium is still the most effective agent, and if a patient can tolerate it relatively well and responds to it, lithium can be the treatment of first choice. The comparative study of lithium's effects with the effects of other medications shown to be effective in bipolar disorder is an important psychopharmacologic strategy that should lead to a better understanding of its pathophysiology and ultimately to further drug development in this field. Future studies examining the actions of lithium, anticonvulsants, and calcium channel blockers in various membrane, neurotransmitter, and signal transduction processes may provide the path to achieve these goals.

Drug names: carbamazepine (Tegretol and others), chlorpromazine (Thorazine and others), gabapentin (Neurontin), lamotrigine (Lamictal), nimodipine (Nimotop), verapamil (Calan and others).

Disclosure of off-label usage: The authors have determined that, to the best of their knowledge, the following agents are not approved by the U.S. Food and Drug Administration for the treatment of bipolar disorder: carbamazepine, gabapentin, lamotrigine, nimodipine, verapamil.

REFERENCES

- Gershon S. The possible thymoleptic effect of the lithium ion. *Am J Psychiatry* 1968;124:1452-1456
- Gershon S. Use of lithium salts in psychiatric disorders. *Dis Nerv Syst* 1968;29:51-55
- Gershon S. Psychopharmacology of the lithium ion (twenty years after). *Dis Nerv Syst* 1970;31:333-335
- Cade J. Lithium salts in the treatment of psychotic excitement. *Med J Aust* 1949;14:349-352
- Gershon S, Soares JC. Current therapeutic profile of lithium. *Arch Gen Psychiatry* 1997;54:16-20
- Soares JC, Gershon S. The lithium ion: a foundation for psychopharmacological specificity. *Neuropsychopharmacology* 1998;19:167-182
- Noack CH, Trautner EM. Lithium treatment of maniacal psychosis. *Med J Aust* 1951;18:219-222
- Wynn V. The clinical significance of sodium and potassium. *Med J Aust* 1950;37:821-826
- Trautner EM, Morris R, Noack CH, et al. The excretion and retention of ingested lithium and its effect on the ionic balance of man. *Med J Aust* 1955;2:280-291
- Plichet A. Le traitement des états maniaques par les sels de lithium. *Presse Med* 1954;62:869
- Teulie M, Follin W, Begoin M. Etude de l'action des sels de lithium aux états d'excitation psychomotrice. *Encephale* 1955;44:266
- Guistino P. Il citrato di litio nel trattamento degli stati di eccitazione psicotica. *Note Psychiatry* 1953;79:307-311
- Andreani G, Caselli G, Martelli G. *J Psychiatry Neuropatol* 1958;86:278-328
- Vojtechovsky M. *Problemy Psychiatrie y Praxi a ve Vyskumu*. Prague, Czechoslovakia: Czechoslovak Medical Press; 1957:216-224
- Hartigan GP. The use of lithium salts in affective disorders. *Br J Psychiatry* 1963;109:810
- Gershon S, Yuwiler A. Lithium ion: a specific psychopharmacological approach to the treatment of mania. *J Neuropsychiatry* 1960;1:229-241
- Kingstone E. The lithium treatment of hypomanic and manic states. *Compr Psychiatry* 1960;1:317-320
- Nassr DG. Observations on the use of lithium carbonate in psychiatry. *Int J Neuropsychiatry* 1966;2:160-165
- Wharton RN, Fieve RR. The use of lithium in the affected psychoses. *Am J Psychiatry* 1966;123:706-712
- Schlagenhauf G, Tupin J, White RB. The use of lithium carbonate in the treatment of manic psychoses. *Am J Psychiatry* 1966;123:201-207
- Calabrese J, Bowden C, Woysville M. Lithium and the anticonvulsants in the treatment of bipolar disorder. In: Bloom F, Kupfer D, eds. *Psychopharmacology: The Fourth Generation of Progress*. New York, NY: Raven Press; 1995:1099-1112
- Calabrese JR, Woysville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. *Ann Clin Psychiatry* 1995;7:103-112
- Price LH, Heninger GR. Lithium in the treatment of mood disorders. *N Engl J Med* 1994;331:591-598
- Prien R, Potter W. NIMH workshop report on treatment of bipolar disorder. *Psychopharmacol Bull* 1990;26:409-427
- Prien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. *Arch Gen Psychiatry* 1972;26:146-153
- Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. *J Affect Disord* 1980;2:279-288
- Goodwin FK, Zis AP. Lithium in the treatment of mania: comparisons with neuroleptics. *Arch Gen Psychiatry* 1979;36:840-844
- Johnson G, Gershon S, Burdock EL, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. *Br J Psychiatry* 1971;119:267-276
- Platman SR. A comparison of lithium carbonate and chlorpromazine in mania. *Am J Psychiatry* 1970;127:351-353
- Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. *Arch Gen Psychiatry* 1975;32:34-42
- Spring G, Schweid D, Gray C, et al. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. *Am J Psychiatry* 1970;126:1306-1310
- Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania: report of collaborative study group on treatment of mania in Japan. *Arch Gen Psychiatry* 1975;32:1310-1318
- Dilsaver SC, Swann AC, Shoaib AM, et al. The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. *J Psychiatry Neurosci* 1993;18:61-66
- Himmelhoch JM, Mulla D, Neil JF, et al. Incidence and significance of mixed affective states in a bipolar population. *Arch Gen Psychiatry* 1976;33:1062-1066
- Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. *J Affect Disord* 1988;15:9-15

36. Secunda SK, Katz MM, Swann A, et al. Mania: diagnosis, state measurement and prediction of treatment response. *J Affect Disord* 1985;8:113–121
37. Swann AC, Secunda SK, Katz MM, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. *Psychiatry Res* 1986;18:127–141
38. Bastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. *Lancet* 1970;2:326–330
39. Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders: controlled trial. *Lancet* 1971;2:275–279
40. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. *Psychol Med* 1972;2:308–311
41. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders, V: a double-blind study of prophylaxis of depression in bipolar illness. *Arch Gen Psychiatry* 1976;33:117–120
42. Fieve RR, Kumbharaci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. *Am J Psychiatry* 1976;133:925–929
43. Hullin RP, McDonald R, Allsopp MN. Prophylactic lithium in recurrent affective disorders. *Lancet* 1972;1:1044–1046
44. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. *Arch Gen Psychiatry* 1973;28:337–341
45. Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis: report of the Veterans Administration and National Institute of Mental Health collaborative study group. *Arch Gen Psychiatry* 1974;31:189–192
46. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. *Arch Gen Psychiatry* 1973;29:420–425
47. Stallone F, Shelley E, Mendlewicz J, et al. The use of lithium in affective disorders, 3: a double-blind study of prophylaxis in bipolar illness. *Am J Psychiatry* 1973;130:1006–1010
48. Coryell W, Endicott J, Maser JD, et al. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. *J Affect Disord* 1995;33:201–206
49. Peselow ED, Fieve RR, Difiglia C, et al. Lithium prophylaxis of bipolar illness: the value of combination treatment. *Br J Psychiatry* 1994;164:208–214
50. Prien RF. Maintenance treatment of depressive and manic states. In: Georgotas R, Cancro R, eds. *Depression and Mania*. New York, NY: Elsevier Science; 1988:439–451
51. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. *Arch Gen Psychiatry* 1984;41:1096–1104
52. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. *Am J Psychiatry* 1992;149:1633–1644
53. Moncrieff J. Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. *Br J Psychiatry* 1995;167:569–573
54. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness and efficiency. *Br J Psychiatry* 1994;164:741–746
55. Maj M. Lithium prophylaxis of schizoaffective disorders: a prospective study. *J Affect Disord* 1988;14:129–135
56. Faedda GL, Baldessarini RJ, Tohen N, et al. Episode sequence in bipolar disorder and response to lithium treatment. *Am J Psychiatry* 1991;148:1237–1239
57. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. *JAMA* 1994;271:918–924
58. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. *J Clin Psychopharmacol* 1992;12:42S–52S
59. Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five year prospective follow-up. *J Nerv Ment Dis* 1993;181:238–245
60. Sharma V, Persad E. Pharmacotherapy of rapid cycling bipolar disorder: a review. *Lithium* 1994;5:117–125
61. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. *Prog Neuropsychopharmacol Biol Psychiatry* 1981;5:507–510
62. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? *J Affect Disord* 1986;10:115–125
63. Kutcher SP, Marton P, Korenblum M. Adolescent bipolar illness and personality disorder. *J Am Acad Child Adolesc Psychiatry* 1990;29:355–358
64. Gaviria M, Flaherty J, Val E. A comparison of bipolar patients with and without a borderline personality disorder. *Psychiatr J Univ Ottawa* 1982;7:190–195
65. Abou-Saleh MT. Platelet MAO: personality and response to lithium prophylaxis. *J Affect Disord* 1983;5:58–65
66. Maj M. Effectiveness of lithium prophylaxis in schizoaffective psychosis: application of a polydiagnostic approach. *Acta Psychiatr Scand* 1984;70:228–234
67. Mendlewicz J, Stallone F. Generic factors and lithium response in manic-depressive illness. *Mod Prob Pharmacopsychiatry* 1975;10:23–29
68. Grof P, Alda M, Grof E, et al. The challenge of predicting response to stabilizing lithium treatment: the importance of patient selection. *Br J Psychiatry* 1993;21:16–19
69. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. *Arch Gen Psychiatry* 1982;39:1065–1069
70. Baron M, Gershon ES, Rudy V, et al. Lithium carbonate response in depression: prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. *Arch Gen Psychiatry* 1975;32:1107–1111
71. Goodwin FK, Murphy DL, Dunner DL, et al. Lithium response in unipolar versus bipolar depression. *Am J Psychiatry* 1972;129:44–47
72. Mendels J, Ramsey TA, Dyson WL, et al. Lithium as an antidepressant. *Arch Gen Psychiatry* 1979;36:845–846
73. Noyes R Jr, Dempsey GM, Blum A, et al. Lithium treatment of depression. *Compr Psychiatry* 1974;15:187–193
74. Fieve RR, Dunner DL, Kumbharaci T, et al. Lithium carbonate in affective disorders, IV: a double-blind study of prophylaxis in unipolar recurrent depression. *Arch Gen Psychiatry* 1975;32:1541–1544
75. Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. *Psychol Med* 1984;14:37–50
76. Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: a clinical trial. *Int Clin Psychopharmacol* 1987;2:47–54
77. Mendels J, Secunda SK, Dyson WL. A controlled study of the antidepressant effects of lithium carbonate. *Arch Gen Psychiatry* 1972;26:154–157
78. de Montigny C. Lithium addition in treatment-resistant depression. *Int Clin Psychopharmacol* 1994;9(suppl 2):31–35
79. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. *Arch Gen Psychiatry* 1983;40:1335–1342
80. Johnson G. Differential response to lithium carbonate in manic depressive and schizo-affective disorders. *Dis Nerv Syst* 1970;31:613–615
81. Brockington IF, Kendell RE, Kellell JM, et al. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. *Br J Psychiatry* 1978;133:162–168
82. Brockington IF, Wainwright S, Kendell RE. Manic patients with schizophrenic or paranoid symptoms. *Psychol Med* 1980;10:73–83
83. Miller FT, Libman H. Lithium carbonate in the treatment of schizophrenia and schizoaffective disorder: review and hypothesis. *Biol Psychiatry* 1979;14:705–710
84. Prien RF, Klett CJ, Caffey EM Jr. Lithium prophylaxis in recurrent affective illness. *Am J Psychiatry* 1974;131:198–203
85. Hirschowitz J, Casper R, Garver DL, et al. Lithium response in good prognosis schizophrenia. *Am J Psychiatry* 1980;137:916–920
86. Schexnayder LW, Hirschowitz J, Sautter FJ, et al. Predictors of response to lithium in patients with psychoses. *Am J Psychiatry* 1995;152:1511–1513
87. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs chlorpromazine in acute schizophrenics. *Br J Psychiatry* 1971;119:435–440
88. Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: do we really have an answer? *J Clin Psychiatry* 1989;50:170–173
89. Delve N, Letemendia F. Lithium treatment in schizophrenia and schizoaffective disorders. *Br J Psychiatry* 1982;141:387–400
90. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 1995;34:445–453
91. DeLong GR, Nieman GW. Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness. *Psychopharmacol Bull* 1983;19:258–265

92. Marini JL, Sheard MH. Antiaggressive effect of lithium ion in man. *Acta Psychiatr Scand* 1977;55:269–286
93. Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. *Am J Psychiatry* 1976;133:1409–1413
94. Siassi I. Lithium treatment of impulsive behavior in children. *J Clin Psychiatry* 1982;43:482–484
95. Tyrer SP, Walsh A, Edwards DE, et al. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. *Prog Neuropsychopharmacol Biol Psychiatry* 1984;8:751–755
96. Wren JC, Kline NS, Cooper TB, et al. Evaluation of lithium therapy in chronic alcoholism. *Clin Med* 1974;81:33–36
97. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. *JAMA* 1989;262:1646–1652
98. Lejoyeux M, Ades J. Evaluation of lithium treatment in alcoholism. *Alcohol Alcohol* 1993;28:273–279
99. Pond SM, Becker CE, Vandervoort R, et al. An evaluation of the effects of lithium in the treatment of chronic alcoholism, I: clinical results. *Alcohol Clin Exp Res* 1981;5:247–251
100. Merry J, Reynolds CM, Bailey J, et al. Prophylactic treatment of alcoholism by lithium carbonate: a controlled study. *Lancet* 1976;1:481–482
101. Cronson AJ, Flemenbaum A. Antagonism of cocaine highs by lithium. *Am J Psychiatry* 1978;135:856–857
102. Nunes EV, McGrath PJ, Wager S, et al. Lithium treatment for cocaine abusers with bipolar spectrum disorders. *Am J Psychiatry* 1990;147:655–657
103. McDougale CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. *J Clin Psychopharmacol* 1991;11:175–184
104. Mattsson B, von Schoultz B. A comparison between lithium, placebo and a diuretic in premenstrual tension. *Acta Psychiatr Scand* 1974;255:75–84
105. Singer K, Cheng R, Schou M. A controlled evaluation of lithium in the premenstrual tension syndrome. *Br J Psychiatry* 1974;124:50–51
106. Goldberg MA. The treatment of Kleine-Levin syndrome with lithium. *Can J Psychiatry* 1983;28:491–493
107. Hsu LK. Treatment of bulimia with lithium. *Am J Psychiatry* 1984;141:1260–1262
108. Moskowitz JA. Lithium and lady luck: use of lithium carbonate in compulsive gambling. *N Y State J Med* 1990;80:785–788
109. Will RG, Young JP, Thomas DJ. Kleine-Levin syndrome: report of two cases with onset of symptoms precipitated by head trauma. *Br J Psychiatry* 1988;152:410–412
110. Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. *Folia Psychiatr Neurol Jpn* 1973;27:283–297
111. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. *Acta Psychiatr Scand* 1992;85:114–118
112. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. *J Clin Psychiatry* 1987;48:89–93
113. Luszkat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. *Br J Psychiatry* 1988;153:198–204
114. Okuma T, Yamashita I, Takahashi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. *Pharmacopsychiatry* 1990;23:143–150
115. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. *Arch Gen Psychiatry* 1991;48:915–921
116. Watkins SE, Callender K, Thomas DR, et al. The effect of carbamazepine and lithium on remission from affective illness. *Br J Psychiatry* 1987;150:180–182
117. Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. *Br J Psychiatry* 1995;166:378–381
118. Ballenger JC. The clinical use of carbamazepine in affective disorders. *J Clin Psychiatry* 1988;49(4, suppl):13–21
119. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. *Acta Psychiatr Scand* 1991;83:456–459
120. Folks DG, King LD, Dowdy SB, et al. Carbamazepine treatment of selected affectively disordered inpatients. *Am J Psychiatry* 1982;139:115–117
121. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. *Psychiatry Res* 1987;21:71–83
122. Post RM, Frye MA, Denicoff KD, et al. Beyond lithium in the treatment of bipolar illness. *Neuropsychopharmacology* 1998;19:206–219
123. Bowden CL, Davis J, Morris D, et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. *Depress Anxiety* 1997;6:26–30
124. Clothier J, Swann AC, Freeman T. Dysphoric mania. *J Clin Psychopharmacol* 1992;12:13S–16S
125. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. *Am J Psychiatry* 1992;149:108–111
126. Bowden CL. Predictors of response to divalproex and lithium. *J Clin Psychiatry* 1995;56(suppl 3):25–30
127. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. *Neuropsychopharmacology* 1998;19:194–199
128. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. *J Clin Psychopharmacol* 1994;14:311–313
129. Calabrese JR, Fatemi SH, Woysville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. *Am J Psychiatry* 1996;153:1236
130. Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical studies on the use of lamotrigine in bipolar disorder. *Neuropsychobiology* 1998;38:185–191
131. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. *J Clin Psychopharmacol* 1997;17:185–189
132. Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. *J Clin Psychiatry* 1997;58:522–527
133. Kusumakar V, Yatham L. An open study of lamotrigine in refractory bipolar depression. *Psychiatry Res* 1997;72:145–148
134. Erfurth A, Kammerer C, Grunze H, et al. An open label study of gabapentin in the treatment of acute mania. *J Psychiatry Res* 1998;32:261–264
135. Ghaemi SN, Katzow JJ, Desai SP, et al. Gabapentin treatment of mood disorders: a preliminary study. *J Clin Psychiatry* 1998;59:426–429
136. Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. *J Affect Disord* 1998;49:229–233
137. McElroy SL, Soutullo CA, Keck PE Jr, et al. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. *Ann Clin Psychiatry* 1997;9:99–103
138. Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with gabapentin. *Biol Psychiatry* 1997;42:851–853
139. Pande AC. Combination treatment in bipolar disorder [abstract]. *Bipolar Disorders, an Int J Psychiatry Neurosci* 1999;1:17
140. Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. *J Clin Psychopharmacol* 1987;7:101–113
141. Brotman AW, Farhadi AM, Gelenberg AJ. Verapamil treatment of acute mania. *J Clin Psychiatry* 1986;47:136–138
142. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. *Am J Psychiatry* 1992;149:121–122
143. Hoschl C, Kozeny J. Verapamil in affective disorders: a controlled, double-blind study. *Biol Psychiatry* 1989;25:128–140
144. Janicak PG, Sharma RP, Pandey G, et al. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. *Am J Psychiatry* 1998;155:972–973
145. Brunet G, Cerlich B, Robert P, et al. Open trial of a calcium antagonist, nimodipine, in acute mania. *Clin Neuropharmacol* 1990;13:224–228
146. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder [letter]. *J Clin Psychiatry* 1995;56:330
147. Grunze H, Walden J, Wolf R, et al. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. *Prog Neuropsychopharmacol Biol Psychiatry* 1996;20:419–426
148. McDermet W, Pazzaglia P, Huggins T, et al. Use of single case analysis in off-on-off trials in affective illness: a demonstration of the efficacy of nimodipine. *Depression* 1995;2:259–271
149. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. *Psychiatry Res* 1993;49:257–272
150. Post RM, Ketter TA, Pazzaglia PJ, et al. New developments in the use of anticonvulsants as mood stabilizers. *Neuropsychobiology* 1993;27:132–137
151. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. *J Clin Psychiatry* 1997;58:470–478